MODIFIED Form PTO-1595 RECORDATION	V FORM COVER SHEET U.S. DEPARTMENT OF COMMERCE							
(Rev. 10/02) PATE	NTS ONLY U.S. Patent and Trademark Office							
	ce: Please record the attached original documents or copy thereof.							
1. Name of conveying party(ies):	2. Name and address of receiving party(ies):							
Kousuke TANI	ONO PHARMACEUTICAL CO., LTD.							
Kaoru KOBAYASHI	1-5, Doshomachi 2-chome, Chuo-ku, Osaka-shi							
Toru MARUYAMA	OSAKA 541-8526 JAPAN							
Tohru KAMBE Mikio OGAWA								
Tsutomu SHIROYA	01-28-2005							
Additional name(s) of conveying party(ies) attached? Yes No								
3. Nature of conveyance:								
☑ Assignment ☐ Merger	102929459							
☐ Security Agreement ☐ Change of Name								
☐ Other								
	i							
Execution Date: August 30, 2004	Additional name(s) & address(es) attached? ☐ Yes ☐ No							
4. Application number(s) or patent number(s):								
If this document is being filed together with a new application, the execution date of the application is: August 30, 2004								
A. Patent Application No.(s)	B. Patent No.(s)							
Not yet assigned	Not yet assigned							
Additional numbers a	attached? Yes No							
5. Name and address of party to whom correspondence	6. Total number of applications and patents involved:							
concerning document should be mailed:	1							
SUGHRUE MION, PLLC	7. Total fee (37 CFR 3.41): \$40.00							
WASHINGTON OFFICE	☐ Enclosed. ☐ Authorized to be charged to Deposit Account No. 19-4880.							
23373	The USPTO is directed and authorized to charge all required							
CUSTOMER NUMBER	fees, except for the Issue Fee and the Publication Fee, to Deposit							
	Account No. 19-4880. Please also credit any overpayments to said							
	Deposit Account.							
	8. Deposit Account Number: 19-4880							
	(Attach duplicate copy of this page if paying by deposit account)							
DO NOT	USE THIS SPACE							
9. Statement and signature.	rmation is true and correct and any attached copy is a true copy of the							
9. Statement and signature. To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the spin in the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the spin in the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the spin in the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the spin in the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the spin in the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the spin in the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the spin in the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the spin in the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the spin in the best of my knowledge and belief.								
original document.	September 3, 2004							
efful 3 charact #41,579	32,197 Date							
Mark Holand [
Total number of pages including cover sheet, attachments, and documents: 2								
Total number of pages including cover sheet, attachments to: Mail documents to be recorded with required cover sheet information to: MAIL STOP ASSIGNMENT RECORDATION SERVICES MAIL STOP ASSIGNMENT RECORDATION SERVICES								
Director of the U.S. Patent and Trademark Office								
P.O. Box 1450								
Alexandria, VA 22313-1450								

09/08/2004 GFREY1 00000088 194880 10506536 02 FC:8021 40.00 DA

ASSIGNMENT

Whereas, I/we Kousuke TANI, Kaoru KOBAYASHI, Toru MARUYAMA, Tohru KAMBE, Mikio OGAWA and Tsutomu SHIROYA, all of Osaka, Japan

hereinafter called assignor(s), have invented certain improvements in

8-AZAPROSTAGLANDIN DERIVATIVE COMPOUND AND

AGENT COMPRISING THE COMPOUND AS ACTIVE INGREDIENT

and executed an application for Letters Patent of the United States of America therefor on

August 30, 2004; and

Whereas,

Date:

ONO PHARMACEUTICAL CO., LTD. of 1-5, Doshomachi 2-chome, Chuo-ku, Osaka-shi, OSAKA 541-8526 JAPAN

(assignee), desires to acquire the entire right, title and interest in the application and invention, and to any United States patents to be obtained therefor;

Now therefore, for valuable consideration, receipt whereof is hereby acknowledged,

I/We, the above named assignor(s), hereby sell, assign and transfer to the above named assignee, its successors and assigns, the entire right, title and interest in the application and the invention disclosed therein for the United States of America, including the right to claim priority under 35 U.S.C. § 119, and I/we request the Director – U.S. Patent and Trademark Office to issue any Letters Patent granted upon the invention set forth in the application to the assignee, its successors and assigns; and I/we will execute without further consideration all papers deemed necessary by the assignee in connection with the United States application when called upon to do so by the assignee.

I/We hereby authorize and request my/our attorneys SUGHRUE MION, PLLC of 2100

Pennsylvania												parenth ing date	
(Application nu	ımber				, tile	a					C 111	ing date	, 4,,,4
application nur	nber of sa	id app	olication	when kn	own.								
Date:	August	30,	2004	s/	K	ousul	ce	Ta	mì_				_
Date:	August	30,	2004	s/	Kao	nu V	day.	ach	<u>i`</u>				_
Date:	August	30,	2004	s/	Tor	u M	laru	yaı	na	<u> </u>			-
Date:	August	30,	2004			ruk							_
Date:	August	30,	2004			lifeio							
Date:	August	30,	2004	s/	Ts	utomu	<u>, 0</u>	hir	ya_				

(Legalization not required for recording but is prima facie evidence of execution under 35 U.S.C. §261)

PATENT RECORDED: 09/03/2004 REEL: 016185 FRAME: 0767